Description:
The World Market for Molecular Diagnostics Tests, 11th Edition provides detailed analysis of the clinical molecular testing industry, focusing on key market segments and their growth prospects. The report includes insights into the business opportunities, new product introductions, and rapid changes shaping the market landscape.
- Market Segments:
- Infectious Disease Molecular Diagnostics:
- Comprehensive coverage of COVID-19, Hepatitis, HIV, Respiratory, STI, and other infectious diseases.
- Cancer Molecular Diagnostic Markets:
- In-depth analysis of blood-based and tissue-based diagnostics.
- Genetic Molecular Diagnostic Markets:
- Focus on SNPs, inherited disorders, NIPT, and other genetic testing markets.
- Blood Banking Molecular Diagnostics Markets
- Transplantation Molecular Diagnostic Markets
- Regional Molecular Diagnostics Markets:
- Detailed market assessments for North America, Europe, Asia, and the global landscape.
- Infectious Disease Molecular Diagnostics:
Why This Report is Essential:
Kalorama Information’s The World Market for Molecular Diagnostics Tests, 11th Edition is an indispensable tool for stakeholders in the healthcare and diagnostics industries. This report offers a thorough analysis of market dynamics, regional growth, and segment-specific forecasts, equipping you with the insights needed to navigate and succeed in this competitive market.
Key Insights:
- Industry Impact:
- Molecular diagnostics proved their immense value during the COVID-19 pandemic, highlighting the importance of rapid and accurate testing.
- The heavily competitive market in 2023 demonstrates the need for market leaders to anticipate quick and rapid changes.
For further details and to purchase directly, please contact us.
Sample Report: A sample is available as a PDF upon request.
Table: Molecular Diagnostic Market, by Segment, 2022-2027 (in millions $)
| Segment | 2022 | 2027 | CAGR (%) |
| HAIs/ sepsis | $XX Million | $XX Million | XX% |
| Hepatitis | $XX Million | $XX Million | XX% |
| HIV | $XX Million | $XX Million | XX% |
| STIs | $XX Million | $XX Million | XX% |
| Respiratory | $XX Million | $XX Million | XX% |
| TB | $XX Million | $XX Million | XX% |
| Total Infectious, non COVID | $XX Million | $XX Million | XX% |
| Cancer Assays* | $XX Million | $XX Million | XX% |
| Histology (ISH, FISH) | $XX Million | $XX Million | XX% |
| Molecular HPV | $XX Million | $XX Million | XX% |
| Total Oncology | $XX Million | $XX Million | XX% |
| NAT Blood Screening | $XX Million | $XX Million | XX% |
| NIPT | $XX Million | $XX Million | XX% |
| Thrombophilia/SNPs | $XX Million | $XX Million | XX% |
| Pharmacogenomics | $XX Million | $XX Million | XX% |
| Inherited/ genetic | $XX Million | $XX Million | XX% |
| Transplantation | $XX Million | $XX Million | XX% |
| TOTAL | $XX Million | $XX Million | XX% |
Source: Kalorama Information
